Aprogen Biologics Inc.

A003060

KR7003060001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-25 pm EDT			5-day change	1st Jan Change
1,011 ^KRW	-0.39%		-2.79%	-65.14%

Mar. 13	Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 03:01 am EDT

Aprogen Biologics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 437.74 million compared to KRW 14.97 million a year ago. Net income was KRW 1,102.97 million compared to KRW 2,826.16 million a year ago.

Basic earnings per share from continuing operations was KRW 20 compared to KRW 70 a year ago. Diluted earnings per share from continuing operations was KRW 20 compared to KRW 70 a year ago. Basic earnings per share was KRW 20 compared to KRW 70 a year ago.

Latest news about Aprogen Biologics Inc.

Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Aprogen Biologics Inc.(KOSE:A003060) dropped from S&P Global BMI Index	23-09-18	CI
Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Aprogen Biologics Inc. announced that it has received KRW 20 billion in funding from Aprogen, Inc.	23-04-23	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 20 billion in funding from Aprogen, Inc.	23-04-20	CI
Aprogen Biologics Inc. announced that it has received KRW 40 billion in funding	23-04-13	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 40 billion in funding	23-04-12	CI
Aprogen Biologics Inc. announced that it has received KRW 40.0000005 billion in funding from Aprogen Medicines Inc.	23-04-11	CI
Aprogen pharmaceuticals,Inc. completed the acquisition of Aprogen Biologics Inc. from Aprogen, Inc.	22-12-30	CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Aprogen Pharmaceuticals to Raise $35.1 Million Through Stock Issuance	22-10-04	MT
Aprogen pharmaceuticals,Inc. agreed to acquire Aprogen Biologics Inc. from Aprogen, Inc.	22-10-03	CI
Aprogen Biologics Inc. announced that it expects to receive KRW 50 billion in funding from Aprogen Medicines Inc.	22-10-03	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-14	CI
Aprogen pharmaceuticals,Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Aprogen Medicines Inc. announced that it expects to receive KRW 105 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd., Aprogen pharmaceuticals,Inc., Aprogen Healthcare & Games Inc.	21-09-15	CI
Immunotech Biopharm : Hires Aprogen Director as New Tech Chief	21-04-14	MT
Aprogen KIC Inc. cancelled the acquisition of additional 5.6% stake in Aprogen pharmaceuticals,Inc..	21-01-13	CI
Aprogen KIC Inc. agreed to acquire additional 5.6% stake in Aprogen pharmaceuticals,Inc. for KRW 17.8 billion.	20-01-13	CI
Aprogen pharmaceuticals,Inc. acquired an additional 6.38% stake in Locojoy International Corporation from Aprogen Biologics Inc. for KRW 7 billion.	19-09-29	CI
Aprogen pharmaceuticals,Inc. announced that it has received KRW 20.000000214 billion in funding from Aprogen KIC Inc.	19-08-06	CI

Chart Aprogen Biologics Inc.

Duration

Period

More charts

Company Profile

Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
APROGEN BIOLOGICS INC.	-65.14%	47.97M
ELI LILLY AND COMPANY	+54.61%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+20.62%	337B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+8.61%	171B